Colin Cooper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10615310/publications.pdf

Version: 2024-02-01

516215 940134 2,231 17 16 16 citations h-index g-index papers 17 17 17 5451 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745.	9.4	395
2	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	6.0	348
3	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	5.1	291
4	Multiple loci on 8q24 associated with prostate cancer susceptibility. Nature Genetics, 2009, 41, 1058-1060.	9.4	273
5	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncology, The, 2008, 9, 342-351.	5.1	257
6	Amplification and Overexpression of the KIT Gene Is Associated with Progression in the Seminoma Subtype of Testicular Germ Cell Tumors of Adolescents and Adults. Cancer Research, 2005, 65, 8085-8089.	0.4	149
7	The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget, 2016, 7, 23106-23127.	0.8	128
8	Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology, 2009, 55, 696-704.	1.6	85
9	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	2.4	69
10	Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. Scientific Reports, 2017, 7, 5901.	1.6	49
11	PRKC-Â Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. Genes and Cancer, 2010, 1, 444-464.	0.6	46
12	Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene, 2004, 23, 9142-9147.	2.6	38
13	Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1 $\hat{l}\pm$ and sphingosine kinase 1. Oncotarget, 2016, 7, 80943-80956.	0.8	32
14	A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clinical Epigenetics, 2018, 10, 147.	1.8	26
15	New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. Breast Cancer Research and Treatment, 2017, 165, 531-543.	1.1	24
16	Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing. Journal of Clinical Pathology, 2015, 68, 212-217.	1.0	21
17	Truncation of BRAF and Raf1 in prostate cancer in China Journal of Clinical Oncology, 2012, 30, 77-77.	0.8	0